192 related articles for article (PubMed ID: 19486799)
1. Endophthalmitis after anti-VEGF injections.
Klein KS; Walsh MK; Hassan TS; Halperin LS; Castellarin AA; Roth D; Driscoll S; Prenner JL
Ophthalmology; 2009 Jun; 116(6):1225.e1. PubMed ID: 19486799
[No Abstract] [Full Text] [Related]
2. Re: Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
Ranchod TM; Leverenz VR; Chintala SK; Cheng M; Trese MT; Giblin FJ
Retina; 2010; 30(10):1752-4; author reply 1754. PubMed ID: 21060278
[No Abstract] [Full Text] [Related]
3. Endophthalmitis associated with intravitreal anti-vascular endothelial growth factor therapy injections in an office setting.
Pilli S; Kotsolis A; Spaide RF; Slakter J; Freund KB; Sorenson J; Klancnik J; Cooney M
Am J Ophthalmol; 2008 May; 145(5):879-82. PubMed ID: 18329624
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of intravitreal anti-VEGF injections for age-related macular degeneration.
Jeganathan VS; Verma N
Curr Opin Ophthalmol; 2009 May; 20(3):223-5. PubMed ID: 19367163
[TBL] [Abstract][Full Text] [Related]
5. [Introduction to the topic: anti-VEGF therapy in the management of AMD].
Meyer CH
Ophthalmologe; 2008 Feb; 105(2):123-4. PubMed ID: 18256843
[No Abstract] [Full Text] [Related]
6. Endophthalmitis after intravitreal vascular [corrected] endothelial growth factor antagonists: a six-year experience at a university referral center.
Moshfeghi AA; Rosenfeld PJ; Flynn HW; Schwartz SG; Davis JL; Murray TG; Smiddy WE; Berrocal AM; Dubovy SR; Lee WH; Albini TA; Lalwani GA; Kovach JL; Puliafito CA
Retina; 2011 Apr; 31(4):662-8. PubMed ID: 21836400
[TBL] [Abstract][Full Text] [Related]
7. Complications of subspecialty ophthalmic care: endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications.
Haddock LJ; Ramsey DJ; Young LH
Semin Ophthalmol; 2014; 29(5-6):257-62. PubMed ID: 25325851
[TBL] [Abstract][Full Text] [Related]
8. Ocular complications after anti-vascular endothelial growth factor therapy in Medicare patients with age-related macular degeneration.
Day S; Acquah K; Mruthyunjaya P; Grossman DS; Lee PP; Sloan FA
Am J Ophthalmol; 2011 Aug; 152(2):266-72. PubMed ID: 21664593
[TBL] [Abstract][Full Text] [Related]
9. Infectious endophthalmitis after intravitreal injection of antiangiogenic agents.
Diago T; McCannel CA; Bakri SJ; Pulido JS; Edwards AO; Pach JM
Retina; 2009 May; 29(5):601-5. PubMed ID: 19357558
[TBL] [Abstract][Full Text] [Related]
10. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
[TBL] [Abstract][Full Text] [Related]
11. Intraocular inflammation after intravitreal ranibizumab injections.
Fauser S; Schroeder S; Caramoy A; Kirchhof B; Lappas A
Acta Ophthalmol; 2011 Feb; 89(1):e98-9. PubMed ID: 20384590
[No Abstract] [Full Text] [Related]
12. Incidence of presumed endophthalmitis after intravitreal injection performed in the operating room: a retrospective multicenter study.
Casparis H; Wolfensberger TJ; Becker M; Eich G; Graf N; Ambresin A; Mantel I; Michels S
Retina; 2014 Jan; 34(1):12-7. PubMed ID: 23945639
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of safety for bilateral same-day intravitreal injections of antivascular endothelial growth factor therapy.
Lima LH; Zweifel SA; Engelbert M; Sorenson JA; Slakter JS; Cooney MJ; Klancnik JM; Yannuzzi LA; Freund KB
Retina; 2009 Oct; 29(9):1213-7. PubMed ID: 19934815
[TBL] [Abstract][Full Text] [Related]
14. Vitreous inflammation associated with intravitreal anti-VEGF pharmacotherapy.
Agrawal S; Joshi M; Christoforidis JB
Mediators Inflamm; 2013; 2013():943409. PubMed ID: 24307762
[TBL] [Abstract][Full Text] [Related]
15. Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.
Waisbourd M; Loewenstein A; Goldstein M; Leibovitch I
Drugs Aging; 2007; 24(8):643-62. PubMed ID: 17702534
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of neovascular age-related macular degeneration with bevacizumab].
Monzón Moreno A
Farm Hosp; 2006; 30(6):387-8. PubMed ID: 17298199
[No Abstract] [Full Text] [Related]
17. Incidence of acute onset endophthalmitis following intravitreal bevacizumab (Avastin) injection.
Mason JO; White MF; Feist RM; Thomley ML; Albert MA; Persaud TO; Yunker JJ; Vail RS
Retina; 2008 Apr; 28(4):564-7. PubMed ID: 18398358
[TBL] [Abstract][Full Text] [Related]
18. The safety of using anti-VEGF: Is there strength in numbers? Curtis LH, Hammill BG, Schulman KA, Cousins SW (2010) Risks of mortality, myocardial infarction, bleeding, and stroke associated with therapies for age-related macular degeneration. Arch Ophthalmol 128(10):1273-1279.
Wong D; Joussen AM
Graefes Arch Clin Exp Ophthalmol; 2011 Feb; 249(2):161-2. PubMed ID: 21210141
[No Abstract] [Full Text] [Related]
19. Ranibizumab for exudative age-related macular degeneration in eyes previously treated with alternative vascular endothelial growth factor inhibitors.
Ehlers JP; Spirn MJ; Shah CP; Fenton GL; Baker PS; Regillo CD; Ho AC
Ophthalmic Surg Lasers Imaging; 2010; 41(2):182-9. PubMed ID: 20307035
[TBL] [Abstract][Full Text] [Related]
20. Bevacizumab: not as good with more adverse reactions?
Beaumont P
Clin Exp Ophthalmol; 2011 Aug; 39(6):588-90. PubMed ID: 21631687
[No Abstract] [Full Text] [Related]
[Next] [New Search]
